MANNKIND CORP Increase (Decrease) in Other Operating Liabilities
MANNKIND CORP (MNKD) reported Increase (Decrease) in Other Operating Liabilities of $721.00 thousand for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2018-02-27
- MANNKIND CORP increase (decrease) in other operating liabilities for the quarter ending 2016-03-31 was $721.00K, a 1.55% increase year-over-year.
- MANNKIND CORP increase (decrease) in other operating liabilities for the quarter ending 2015-12-31 was -$2.16M.
- MANNKIND CORP increase (decrease) in other operating liabilities for the quarter ending 2015-09-30 was $2.16M, a 188.02% increase year-over-year.
- MANNKIND CORP increase (decrease) in other operating liabilities for the quarter ending 2015-06-30 was -$680.00K, a 194.31% decline year-over-year.
- MANNKIND CORP increase (decrease) in other operating liabilities for fiscal 2015 was $33.00K, a 57.14% increase from fiscal 2014.
- MANNKIND CORP increase (decrease) in other operating liabilities for fiscal 2014 was $21.00K, a 96.45% decline from fiscal 2013.
- MANNKIND CORP increase (decrease) in other operating liabilities for fiscal 2013 was $591.00K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month | Increase (Decrease) in Other Operating Liabilities 12 month as first filed | Increase (Decrease) in Other Operating Liabilities 244 month | Increase (Decrease) in Other Operating Liabilities 247 month | Increase (Decrease) in Other Operating Liabilities 250 month | Increase (Decrease) in Other Operating Liabilities 253 month | Increase (Decrease) in Other Operating Liabilities 256 month | Increase (Decrease) in Other Operating Liabilities 259 month | Increase (Decrease) in Other Operating Liabilities 263 month | Increase (Decrease) in Other Operating Liabilities 265 month | Increase (Decrease) in Other Operating Liabilities 268 month | Increase (Decrease) in Other Operating Liabilities 271 month | Increase (Decrease) in Other Operating Liabilities 275 month | Increase (Decrease) in Other Operating Liabilities 277 month | Increase (Decrease) in Other Operating Liabilities 280 month | Increase (Decrease) in Other Operating Liabilities 283 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-03-31 | $721.00K 10-Q · filed 2016-05-09 | -$1.44M derived: sum of 2 quarters · filed 2018-02-27 | $724.00K derived: sum of 3 quarters · filed 2018-02-27 | $44.00K derived: sum of 4 quarters · filed 2018-02-27 | |||||||||||||||||
| 2015-12-31 | -$2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $3.00K derived: sum of 2 quarters · filed 2018-02-27 | -$677.00K derived: sum of 3 quarters · filed 2018-02-27 | $33.00K 10-K · filed 2018-02-27 | $2.93M 10-K · filed 2016-03-15 | ||||||||||||||||
| 2015-09-30 | $2.16M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2015-11-09 | $1.48M derived: sum of 2 quarters · filed 2016-08-10 | $2.19M 10-Q · filed 2015-11-09 | $28.00K derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||||||||
| 2015-06-30 | -$680.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2016-08-10 | $30.00K 10-Q/A · filed 2016-08-10 | $1.47M 10-Q · filed 2015-08-10 | -$2.13M derived: sum of 3 quarters · filed 2017-03-16 | -$1.38M derived: sum of 4 quarters · filed 2017-03-16 | ||||||||||||||||
| 2015-03-31 | $710.00K 10-Q · filed 2016-05-09 | $743.00K 10-Q · filed 2015-05-11 | -$1.46M derived: sum of 2 quarters · filed 2017-03-16 | -$704.00K derived: sum of 3 quarters · filed 2017-03-16 | $17.00K derived: sum of 4 quarters · filed 2017-03-16 | ||||||||||||||||
| 2014-12-31 | -$2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$1.41M derived: sum of 2 quarters · filed 2017-03-16 | -$693.00K derived: sum of 3 quarters · filed 2017-03-16 | $21.00K 10-K · filed 2017-03-16 | $2.92M 10-K · filed 2015-03-02 | ||||||||||||||||
| 2014-09-30 | $751.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $1.47M derived: sum of 2 quarters · filed 2015-11-09 | $2.19M 10-Q · filed 2015-11-09 | $2.77M 10-Q · filed 2014-11-10 | |||||||||||||||||
| 2014-06-30 | $721.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $1.44M 10-Q · filed 2015-08-10 | $2.02M 10-Q · filed 2014-08-11 | ||||||||||||||||||
| 2014-03-31 | $714.00K 10-Q · filed 2015-05-11 | $1.30M 10-Q · filed 2014-05-12 | |||||||||||||||||||
| 2013-12-31 | $591.00K 10-K · filed 2016-03-15 | $589.00K 10-K · filed 2014-03-03 | |||||||||||||||||||
| 2013-09-30 | -$2.00K 10-Q · filed 2013-11-12 | ||||||||||||||||||||
| 2013-06-30 | -$2.00K 10-Q · filed 2013-08-09 | ||||||||||||||||||||
| 2013-03-31 | -$2.00K 10-Q · filed 2013-05-10 | ||||||||||||||||||||
| 2012-12-31 | -$2.00K 10-K · filed 2013-03-18 | ||||||||||||||||||||
| 2012-09-30 | -$2.00K 10-Q · filed 2012-11-09 | ||||||||||||||||||||
| 2012-06-30 | -$2.00K 10-Q · filed 2012-08-09 | ||||||||||||||||||||
| 2012-03-31 | -$2.00K 10-Q · filed 2012-05-10 | ||||||||||||||||||||
| 2011-12-31 | -$2.00K 10-K · filed 2012-03-15 | ||||||||||||||||||||
| 2011-09-30 | -$2.00K 10-Q · filed 2011-11-04 | ||||||||||||||||||||
| 2011-06-30 | -$2.00K 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |